Research Papers:

Inhibition of SDF-1-induced migration of oncogene-driven myeloid leukemia by the L-RNA aptamer (Spiegelmer), NOX-A12, and potentiation of tyrosine kinase inhibition

Ellen L. Weisberg _, Martin Sattler, Abdel Kareem Azab, Dirk Eulberg, Anna Kruschinski, Paul W. Manley, Richard Stone and James D. Griffin

PDF  |  HTML  |  Supplementary Files  |  How to cite

Oncotarget. 2017; 8:109973-109984. https://doi.org/10.18632/oncotarget.22409

Metrics: PDF 1681 views  |   HTML 3967 views  |   ?  


Ellen L. Weisberg1,4, Martin Sattler1,4, Abdel Kareem Azab1,4, Dirk Eulberg3, Anna Kruschinski3, Paul W. Manley2, Richard Stone1,4 and James D. Griffin1,4

1Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02215, USA

2Novartis Institutes of Biomedical Research, CH-4002 Basel, Switzerland

3Noxxon Pharma, Max-Dohrn-Strasse 8-10, 10589 Berlin, Germany

4Department of Medicine, Harvard Medical School, Boston, MA 02115, USA

Correspondence to:

Ellen L. Weisberg, email: [email protected]

James D. Griffin, email: [email protected]

Keywords: chronic myeloid leukemia; SDF-1; NOX-A12; nilotinib; drug resistance

Received: July 08, 2017     Accepted: October 25, 2017     Published: November 06, 2017


Resistance to targeted tyrosine kinase inhibitors (TKI) remains a challenge for the treatment of myeloid leukemias. Following treatment with TKIs, the bone marrow microenvironment has been found to harbor a small pool of surviving leukemic CD34+ progenitor cells. The long-term survival of these leukemic cells has been attributed, at least in part, to the protective effects of bone marrow stroma. We found that the NOX-A12 'Spiegelmer', an L-enantiomeric RNA oligonucleotide that inhibits SDF-1α, showed in vitro and in vivo activity against BCR-ABL- and FLT3-ITD-dependent leukemia cells. NOX-A12 was sufficient to suppress SDF-1-induced migration in vitro. The combination of NOX-A12 with TKIs reduced cell migration in the same in vitro model of SDF-1-induced chemotaxis to a greater extent than either drug alone, suggesting positive cooperativity as a result of the SDF-1 blocking function of NOX-A12 and cytotoxicity resulting from targeted oncogenic kinase inhibition. These results are consistent with our in vivo findings using a functional pre-clinical mouse model of chronic myeloid leukemia (CML), whereby we demonstrated the ability of NOX-A12, combined with the ABL kinase inhibitor, nilotinib, to reduce the leukemia burden in mice to a greater extent than either agent alone. Overall, the data support the idea of using SDF-1 inhibition in combination with targeted kinase inhibition to override drug resistance in oncogene-driven leukemia to significantly diminish or eradicate residual leukemic disease.

Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 22409